2.50
Hdl Handle:
http://hdl.handle.net/10541/55821
Title:
Epidermal growth factor receptor-targeted therapy.
Authors:
West, Catharine M L; Joseph, L; Bhana, Sara
Abstract:
High epidermal growth factor receptor (EGFR) expression is a feature of human tumours and is an adverse prognostic factor for radiotherapy outcome. High expression is associated with benefit from accelerated radiotherapy in patients with head and neck squamous cell carcinoma. Anti-EGFR strategies potentiate the effects of radiotherapy and the inhibition of deoxyribonucleic acid repair appears to be important amongst a wide range of mechanisms, which include effects on angiogenesis, differentiation and the immunological response. There is considerable interest in exploring combined modality therapies involving radiation and EGFR antagonists for the curative treatment of cancer patients. Important issues in designing new trials are to investigate optimal scheduling and to establish biobanks to develop biomarkers for future patient selection.
Affiliation:
Academic Radiation Oncology, The University of Manchester, Christie Hospital, Manchester M20 4BX, UK. catharine.west@manchester.ac.uk
Citation:
Epidermal growth factor receptor-targeted therapy. 2008, 81 Spec No 1:S36-44 Br J Radiol
Journal:
The British Journal of Radiology
Issue Date:
Oct-2008
URI:
http://hdl.handle.net/10541/55821
DOI:
10.1259/bjr/32798755
PubMed ID:
18819997
Type:
Article
Language:
en
ISSN:
1748-880X
Appears in Collections:
All Christie Publications ; Academic Department of Radiation Oncology - ADRO

Full metadata record

DC FieldValue Language
dc.contributor.authorWest, Catharine M L-
dc.contributor.authorJoseph, L-
dc.contributor.authorBhana, Sara-
dc.date.accessioned2009-03-16T17:19:13Z-
dc.date.available2009-03-16T17:19:13Z-
dc.date.issued2008-10-
dc.identifier.citationEpidermal growth factor receptor-targeted therapy. 2008, 81 Spec No 1:S36-44 Br J Radiolen
dc.identifier.issn1748-880X-
dc.identifier.pmid18819997-
dc.identifier.doi10.1259/bjr/32798755-
dc.identifier.urihttp://hdl.handle.net/10541/55821-
dc.description.abstractHigh epidermal growth factor receptor (EGFR) expression is a feature of human tumours and is an adverse prognostic factor for radiotherapy outcome. High expression is associated with benefit from accelerated radiotherapy in patients with head and neck squamous cell carcinoma. Anti-EGFR strategies potentiate the effects of radiotherapy and the inhibition of deoxyribonucleic acid repair appears to be important amongst a wide range of mechanisms, which include effects on angiogenesis, differentiation and the immunological response. There is considerable interest in exploring combined modality therapies involving radiation and EGFR antagonists for the curative treatment of cancer patients. Important issues in designing new trials are to investigate optimal scheduling and to establish biobanks to develop biomarkers for future patient selection.en
dc.language.isoenen
dc.subjectEGFRen
dc.subjectEpidermal Growth Factor Receptoren
dc.subjectRadiotherapyen
dc.subjectHead and Neck Cancer-
dc.subjectUterine Cervical Cancer-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDNA-
dc.subject.meshFemale-
dc.subject.meshHead and Neck Neoplasms-
dc.subject.meshHumans-
dc.subject.meshPrognosis-
dc.subject.meshProtein-Tyrosine Kinases-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshTreatment Outcome-
dc.subject.meshUterine Cervical Neoplasms-
dc.titleEpidermal growth factor receptor-targeted therapy.en
dc.typeArticleen
dc.contributor.departmentAcademic Radiation Oncology, The University of Manchester, Christie Hospital, Manchester M20 4BX, UK. catharine.west@manchester.ac.uken
dc.identifier.journalThe British Journal of Radiologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.